False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging

Clinical Radiology

Volumn 66, Issue 4, 2011, Pages 366-382

  Culverwell, A D ^a   Scarsbrook, A F ^a   Chowdhury, F U ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL DISEASE; ARTHROPATHY; ARTIFACT; BONE DISEASE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CELL METABOLISM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG UPTAKE; FALSE POSITIVE RESULT; FALSE POSITIVE UPTAKE; GLUCOSE UTILIZATION; HEAD AND NECK DISEASE; HUMAN; INCIDENTAL FINDING; LUNG DISEASE; LYMPHADENOPATHY; MEDIASTINUM DISEASE; OUTCOME ASSESSMENT; PELVIC DISEASE; PRIORITY JOURNAL; RADIATION RESPONSE; REVIEW; WARTHIN TUMOR;

FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952314625     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2010.12.004     Document Type: Review

References (82)

1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405-22. (Pubitemid 43134354)
2. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85. (Pubitemid 46150968)
3. Hilner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/ computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the national oncologic PET registry. J Clin Oncol 2008;26:2155-61.
4. Weber WA. PET for response assessment in oncology: radiotherapy and chemotherapy. Br J Radiol 2005;(Suppl. 28):42-9. (Pubitemid 43154235)
5. Poeppel TD, Krause BJ, Heusner TA, et al. PET/CT for staging and follow-up of patients with malignancies. Eur J Radiol 2009;70:382-92.
6. Shreve PD, Anzai Y,Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics 1999;19:61-77.
7. Gorospe L, Raman S, Echeveste J, et al. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun 2005;26:671-87. (Pubitemid 41073368)
8. Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. RadioGraphics 2006;26:1335-53. (Pubitemid 44518767)
9. 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am J Roentgenol 2007;189:1203-10.
10. Cook GJR. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging 2007;51:235-43. (Pubitemid 47181083)
11. Liu Y, Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med 2010;40:294-315.
12. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5. (Pubitemid 10034639)
13. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
14. Wong WL, Gibson D, Sanghera B, et al. Evaluation of normal FDG uptake in palatine tonsil and its potential value for detecting occult head and neck cancers: a PET CT study. Nucl Med Commun 2007;28:675-80. (Pubitemid 47220400)
15. Heusner TA, Hahn S,HamamiME, et al. Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging 2009;36:1397-406.
16. Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234: 879-85. (Pubitemid 40250832)
17. Blodgett TM, Fukui MB, Synderman CH, et al. Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artefactual FDG uptake. RadioGraphics 2005;25:897-912.
18. 18F fluorodeoxyglucose positron emission tomography/CT. Chest 2005;128:3888-93.
19. Nasseri F, Eftekhari F. Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls. RadioGraphics 2010;30:413-28.
20. Kawano T, Suzuki A, Ishida A, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging 2004;31:831-6. (Pubitemid 38758353)
21. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008;35:95-9.
22. Ozulker T, Ozulker F, Mert M, et al. Clearance of the high intestinal (18) F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging 2010;37:1011-7.
23. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2003;45:266-71. (Pubitemid 47618647)
24. 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 2005;32:549-56.
25. 18F-FDG in the testis: an assessment by PET/CT. Ann Nucl Med 2007;21:405-10.
26. Goethals I, De Vriendt C, Hoste P, et al. Normal uptake of F-18 FDG in the testis as assessed by PET/CT in a pediatric study population. Ann Nucl Med 2009;23:817-20.
27. Paidisetty S, Blodgett TM. Brown fat: atypical locations and appearances encountered in PET/CT. AJR Am J Roentgenol 2009;193:359-66.
28. Shammas A, Lim R, Charon M. Pediatric FDG PET/CT: physiologic uptake, normal variants and benign conditions. RadioGraphics 2009;29: 1467-86.
29. Garcia CA, van Nostrand D, Atkins F, et al. Reduction of brown fat 2-deoxy-2-[F-18]-fluoro-D-glucose uptake by controlled environmental temperature prior to positron emission tomography scan. Mol Imaging Biol 2006;8:24-9.
30. Soderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging 2007;34:1018-22. (Pubitemid 46919548)
31. Lucignani G. Respiratory and cardiac motion correction with 4D PET imaging: shooting at moving targets. Eur J Nucl Med Mol Imaging 2009; 36:315-9.
32. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003;44:240-3.
33. Hany TF, Heuberger J, von Schulthess GK. Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. Eur Radiol 2003;13:2122-7. (Pubitemid 37080747)
34. Ha J-M, Jeong S-Y, Seo Y-S, et al. Incidental focal F-18 FDG accumulation in lung parenchyma without abnormal CT findings. Ann Nucl Med 2009;6:599-603.
35. Beatty JS, Williams HT, Aldridge BA, et al. Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery 2009;146: 274-81.
36. Heller MT, Meltzer CC, Fukul MB, et al. Superphysiologic FDG uptake in the non-paralyzed vocal cord: resolution of a false-positive PET result with combined PET/CT imaging. Clin Positron Imaging 2000;3:207-11.
37. Peter Klussmen J, Wittekindt C, Florian Preuss S, et al. High risk for bilateral warthin tumor in heavy smokers - review of 185 cases. Acta Otolaryngol 2006;126:1213-7. (Pubitemid 44578897)
38. 18F-fluorodeoxyglucose whole-body positron emission tomography and computed tomography: findings at gray-scale and power Doppler ultrasonography and ultrasound-guided fine-needle aspiration biopsy or core biopsy. Eur Radiol 2009;19:2268-74.
39. Sagowski C, Ussmuller J. Clinical diagnosis of salivary gland sarcoidosis (Heerfordt syndrome). HNO 2000;48:613-5. (Pubitemid 30666094)
40. 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006;47:609-15.
41. 18F-FDG PET: sonographic correlation. AJR Am J Roentgenol 2008;191: 598-603.
42. 18F)fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 2009;30:1431-4.
43. Yasuda S, Shohsu A, Ide M, et al. Diffuse F-18 FDG uptake in chronic thyroiditis. Clin Nucl Med 1997;22:341. (Pubitemid 27203438)
44. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
45. Chin AY, Lee KS, Kim B-T, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-50. (Pubitemid 46768487)
46. Chang CY, Tzao C, Lee SC, et al. Incremental value of integrated FDG-PET/ CT in evaluating indeterminate solitary pulmonary nodule for malignancy. Mol Imaging Biol 2010;12:204-9.
47. Kavanagh P, Stevenson AW, Chen MY, et al. Non-neoplastic diseases in the chest showing increased activity on FDG PET. AJR Am J Roentgenol 2004;183:1133-41. (Pubitemid 44185112)
48. Shim SS, Lee KS, Kim B-T, et al. Focal parenchymal lung lesions showing a potential of false-positive and false-negative interpretations on integrated PET/CT. AJR Am J Roentgenol 2006;186:639-48. (Pubitemid 46100250)
49. Su M, Fan Q, Fan C, et al. Lung sequestration and Pott disease masquerading as primary lung cancer with bone metastases on FDG PET/CT. Clin Nucl Med 2009;34:236-8.
50. Abikhzer G, Turpin S, Bigras JL. Infected pacemaker causing septic lung emboli detected on FDG PET/CT. J Nucl Cardiol 2010;17:514-5.
51. Kei PL, Vikram R, Yeung HW, et al. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 2010;194:W401-6.
52. Tatlidil R, Jadvar H, Bading JR, et al. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002;224:783-7. (Pubitemid 34919813)
53. McDermott S, Skehan SJ. Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging 2010;35:55-69.
54. 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. Eur Radiol 2009;19:2171-9.
55. Donadon M, Bona S, Montorsi M, et al. FDG-PET positive granuloma of the liver mimicking local recurrence after hepatic resection of colorectal liver metastasis. Hepatogastroenterol 2010;57:138-9.
56. Sugawara Y, Zasadny KR, Kison PV, et al. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med 1999;40:1456-62. (Pubitemid 29428927)
57. Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol 2008;81:154-6. (Pubitemid 352019632)
58. 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 2009;193:343-8.
59. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-7.
60. 18F-FDG PET. AJR Am J Roentgenol 2007;189:W36-8.
61. Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdomino-perineal or anterior resection. Radiology 2004;232:815-22. (Pubitemid 39100268)
62. Gorenberg M, Bar-Shalom R, Israel O. Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol 2008;81:821-5.
63. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-7. (Pubitemid 46768509)
64. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9. (Pubitemid 34016347)
65. 18F-FDG avidity of pheochromocytoma and paraganglionoma: a new molecular imaging signature? J Nucl Med 2009;50:711-7.
66. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223:780-8. (Pubitemid 34547598)
67. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009;36:1807-12.
68. Cook GJ. PET and PET/CT imaging of skeletal metastases. Cancer Imaging 2010;10:1-8.
69. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumours: standardized uptake value in 52 lesions. Radiology 2001;219:774-7. (Pubitemid 32476270)
70. 18F-FDG PET/CT imaging. Skeletal Radiol 2010. doi:10.1007/s00256-010-0999-9.
71. Patel CN, Smith JT, Rankine JJ, et al. F-18 FDG PET/CT can help differentiate SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) from suspected metastatic bone disease. Clin Nucl Med 2009;34:254-7.
72. 18F-FDG PET diffuse bone marrow uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009;36:1813-21.
73. 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 2006;47:559-65.
74. Liu Y. Orthopaedic surgery-related benign uptake on FDG-PET: case examples and pitfalls. Ann Nucl Med 2009;23:701-8.
75. Chowdhury FU, Sheerin F, Bradley KM, et al. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol 2009;64:675-81.
76. Jacene HA, Stearns V, Wahl RL. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med 2006;31:379-81. (Pubitemid 44315515)
77. 18F] fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2004;25:813-8.
78. Sopov V, Bernstine H, Stern D, et al. The metabolic spectrum of venous thrombotic disorders found on PET/CT. AJR Am J Roentgenol 2009;193: W530-9.
79. 18F-FDG PET/CT: our experience with 96 prostheses. Eur J Nucl Med Mol Imaging 2009;36:850-8.
80. Chen W, Bural GG, Torigian DA, et al. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2009;36:144-51.
81. Otsuka H, Morita N, Yamashita K, et al. FDG-PET/CT for diagnosis and follow-up of vasculitis. J Med Invest 2007;54:345-9. (Pubitemid 350143749)
82. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)